FDA Evaluating Cannabis for Potential Rescheduling

The U.S. Food and Drug Administration (FDA) is reviewing the evidence surrounding the safety and effectiveness of cannabisfda as a medicine in an attempt to determine whether its status as a Schedule 1 drug – which puts it alongside hard drugs such as heroin – is unwarranted, and should be changed.

“FDA conducts for Health and Human Services a scientific and medical analysis of the drug under consideration, which is currently ongoing,” FDA Press Officer Jeff Ventura told the Huffington Post. “HHS then recommends to DEA that the drug be placed in a given schedule. DEA considers HHS’ analysis, conducts its own assessment, and makes a final scheduling proposal in the form of a proposed rule.”

The DEA was required to order the review based on two public citizens’ petitions that asked the agency for a review.

According to Dug Throckmorton, Deputy Director of the FDA; “While DEA is the lead federal agency responsible for regulating controlled substances and enforcing the Controlled Substances Act, FDA, working with NIDA, provides scientific recommendations about the appropriate controls for those substances”. The statement was made during a House Committee on Oversight and Government Reform hearing which took place on Friday. He continues; “To make these recommendations, FDA is responsible for preparing what’s called an eight-factor analysis, which is a document that is used to assess how likely a drug is to be abused”.

According to the Controlled Substances Act, here are the eight factors that must be considered

  • Its actual or relative potential for abuse
  • Scientific evidence of its pharmacological effect, if known
  • The state of current scientific knowledge regarding the drug or other substance
  • Its history and current pattern of abuse
  • The scope, duration, and significance of abuse
  • What, if any, risk there is to the public health
  • Its psychic or physiological dependence liability
  • Whether the substance is an immediate precursor of a substance already controlled under this subchapter

The FDA has not said how long this process might take.

TheJointBlog

7 thoughts on “FDA Evaluating Cannabis for Potential Rescheduling”

  1. Read our History it all has to do with a news paper and the owner his granddaughter made news robbing a bank when she was a hostages guess who?

    Reply
  2. FDA already has lilly’s big pharms THC 2 types classified as a schedule 3 controlled substance. So how can they NOT make God made THC (cannabis a scheduled 3 as well???)

    Reply
  3. Read the history. Marijuana should have never been places there to begin with. It was political and commercial from the get go

    Reply
  4. After 45 Years of use. I know beyound a Shadow of Doubt. that Marijuana is not Addictive. Does Not cause Harmful Affects. You can’t OD with Marijuana as Herion, Crack , Cocaine , etc. The Benifits are numerous CBD OIL derived from the Male plant is Effective in killing Cancer Cells. Stoppi.g Seziures in Both Kids & Adults . Their are a good many more uses. Of Course there are also people who spike the THC levels to unheard of levels , which may not sit well with people . Female plant which THC comes from. Is good for mood changes in a positive form. Good for PTSD AS WELL AS CHRONIC PAIN. As well as stopping neasua. & makes you want to have an appitite. For Cancer patients .

    Reply

Leave a Comment